ArticleThe Analyst2026
Analysis of multiplexed SERS-based lateral flow assays: turning qualitative into quantitative for inflammatory bowel disease monitoring.
Article in The Analyst, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of diagnostic tests that offer rapid and quantitative results can improve the health of patients, suffering from both chronic and acute diseases. Inflammatory bowel disease (IBD) is a chronic autoimmune condition, where a patient can undergo periods of sudden flare-ups and prolonged remission. The current biomarkers of interest are either detected using central laboratory methods, or, are non-specific to IBD. In this work, we develop a series of lateral flow immunoassays for the detection of IBD biomarkers lactoferrin and myeloperoxidase, in an artificial stool matrix. By utilising surface enhanced Raman scattering (SERS) active nanotags, we demonstrate the feasibility of these SERS-based lateral flow immunoassays for proof-of-concept singleplex and duplex detection
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.